

Mitochondrial Myopathy Diagnosis & Treatment Market Development, market Trend, Segmentation and Forecast to 2020.

Mitochondrial Myopathy Diagnosis & Treatment Market: By Type (MELAS, PEO, MERRF, MNGIE, KSS) By Diagnostic Tests By Therapy - Global Forecast Till 2020

PUNE, MAHARASHTRA, INDIA, August 17, 2017 /EINPresswire.com/ -- Market Highlights



Major key Players include
Centogene
AG, GeneDx, Ixchel
Pharma, Khondrion BV,
Mitobridge, NeuroVive
Pharmaceutical AB,"

Market Research Future

Mitochondrial myopathies are diseases of genetic nature associated with mitochondrial diseases caused by certain nuclear DNA deletions. Mitochondrial myopathies affect mitochondria which is responsible for energy production within a cell associated with mitochondrial disease. Thus, they cause low energy and free radical production which results in a variety of symptoms.

As there is no cure for mitochondrial myopathies, the treatment involves only symptomatic treatment to manage the symptoms and to slow the progression of the disease. The

symptomatic treatment includes vitamin therapy, adequate nutrition etc. The mitochondrial myopathies supplement cocktail consist of mixtures of coenzyme Q-10, L-Carnitine, B-Vitamins, Thiamine (B1), Riboflavin (B2), antioxidants such as Vitamin C and Vitamin E etc. Many of these supplements are needed for several key enzymatic steps in the production of energy by mitochondria. For example, Thiamine is a cofactor for pyruvate dehydrogenase complex which improves lactate and pyruvate levels. Vitamins such as B complex include: B3, B6, B12 and folic acid (B9). Folic acid prevents the development of anaemia and helps in the development of healthy new cells.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/3950

Key Findings:

- Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) and Progressive External Ophthalmoplegia (PEO) are the most commonly found conditions in patients with mitochondrial myopathy. The global MELAS diagnosis & treatment market is expected to grow at the CAGR of 19.39% during 2021 to 2025.
- Genetic tests accounted for the largest market share in 2016, and is projected to grow at a CAGR of 10.11% during 2017 to 2020.
- Supportive therapy captured the whole market share in 2016, and is projected to grow at a CAGR of 9.82% during 2017 to 2020.

Key players of Global Mitochondrial myopathy diagnosis & treatment Market:

- Centogene AG,
- GeneDx,
- Ixchel Pharma,
- Khondrion BV,

- Mitobridge,
- NeuroVive Pharmaceutical AB,
- Reata Pharmaceuticals Inc.,
- Stealth Biotherapeutics
- others.

The genetic testing segment is expected to yield high growth with reference to diagnostics for mitochondrial myopathies. Next Generation Sequencing (NGS) is extremely fast as compared to Sanger sequencing and has mostly superseded conventional Sanger sequencing in genome research, and is expected to do so also in the clinical practice. NGS has an advantage such as greater speed, cost, and accuracy which is expected to become the de facto standard for tests for mitochondrial disorders.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on "[Mitochondrial Myopathy Diagnosis & Treatment Market Research Report- Global Forecast till 2020](#)"

Segmentation:

The global mitochondrial myopathy diagnosis & treatment market is segmented on the basis of type, diagnostic tests and therapy.

Segmentation Based on type, the market has been segmented as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), Kearns–Sayre syndrome (KSS), mitochondrial DNA depletion syndrome (MDS), Pearson syndrome, Leigh syndrome, neuropathy, ataxia, and retinitis pigmentosa (NARP).

Segmentation Based on the diagnostic tests, the market has been segmented as genetic tests, muscle biopsy and biochemical test.

Segmentation Based on the therapy, the market has been segmented as supportive therapy and targeted therapy.

Browse full report @ <https://www.marketresearchfuture.com/reports/mitochondrial-myopathy-diagnosis-treatment-market-3950>

Table of Content

- 1 Introduction
 - 1.1 Definition
 - 1.2 Scope of Study
 - 1.3 Research Objective
 - 1.4 Assumptions & Limitations
 - 1.4.1 Assumptions
 - 1.4.2 Limitations
 - 1.5 Market Structure
- 2 Research Methodology
 - 2.1 Research Process
 - 2.2 Primary Research
 - 2.3 Secondary Research
- 3 Market Dynamics
 - 3.1 Introduction
 - 3.2 Drivers

- 3.2.1 Rise in number of mitochondrial myopathy incidence rate and growing number of screening services.
- 3.2.2 Government funding and incentives for rare genetic diseases
- 3.3 Restraints
 - 3.3.1 Poor treatment options and absence of curative treatment
 - 3.3.2 Lack of awareness and diagnosis of the rare mitochondrial disorders
- 3.4 Opportunities
 - 3.4.1 Faster market uptake and low marketing cost
 - 3.4.2 Research and development
- 3.5 Challenges
 - 3.5.1 Rare nature of the disease
 - 3.5.2 Poor understanding of mitochondria and genetics
 - 3.5.3 Cost of drug development and high investment risk
- 4 Market Factor Analysis
 - 4.1 Porter's Five Forces Analysis
 - 4.1.1 Threat from a New Entrant
 - 4.1.2 Bargaining Power of Buyer
 - 4.1.3 Bargaining Power of Supplier
 - 4.1.4 Threat from substitute
 - 4.1.5 Intensity of Competitive Rivalry
 - 4.2 Pipeline Analysis
 - 4.2.1 Introduction
 - 4.2.2 KH176
 - 4.2.3 Elamipretide
 - 4.2.4 RTA 408
 - 4.2.5 IXC 103
 - 4.2.6 NV556
 - 4.3 Mega Trends
 - 4.3.1 Strategies for increasing mitochondrial biogenesis
 - 4.3.2 Antioxidant approaches
 - 4.3.3 Targeting mitochondrial dynamics and biogenesis
 - 4.3.4 Mitochondrial membrane lipids as therapeutic targets
 - 4.3.5 Nucleoside replacement and gene therapy
 - 4.3.6 Enzyme replacement therapy
 - 4.4 Investment Opportunity Analysis
 - 4.4.1 Market size (current and future), growth rate, and profitability
 - 4.4.2 Investment Risks
 - 4.4.3 Market Outlook
 - 4.4.4 Competitors
 - 4.4.5 Projections
- 5 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Type
 - 5.1 Introduction
 - 5.2 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
 - 5.3 Progressive External Ophthalmoplegia (PEO)
 - 5.4 Myoclonic Epilepsy with Ragged Red Fibres (MERRF)
 - 5.5 Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE)
 - 5.6 Kearns–Sayre Syndrome (KSS)
 - 5.7 Mitochondrial DNA Depletion Syndrome (MDS)
 - 5.8 Pearson Syndrome
 - 5.9 Leigh Syndrome
 - 5.10 Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP)
- 6 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Diagnostic Test

Continue.....

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.